Adlai Nortye Group Reveals Oral Presentation For AN4035 Program Update At the Upcoming 38th EORTC-NCI-AACR Symposium

Benzinga · 3d ago

Adlai Nortye Group Ltd. (NASDAQ:ANL) ("Adlai Nortye" or the "Company"), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that an oral presentation on AN4035 will be shared during the 38th EORTC-NCI-AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics, taking place November 18-20 in Barcelona, Spain.